Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cadrenal Therapeutics, Inc. ( (CVKD) ) just unveiled an announcement.
Cadrenal Therapeutics, a late-stage biopharmaceutical firm, has successfully raised $5.1 million through an at-the-market facility, selling over 391,000 shares at $13.15 per share. This capital boost supports the ongoing development of tecarfarin, a new vitamin K antagonist aimed at providing better anticoagulation for patients with cardiac devices or rare cardiovascular conditions. The proceeds also enhance the company’s working capital as it prepares for pivotal clinical trials and explores partnership opportunities.
For detailed information about CVKD stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue